A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease.
II tüüpi diabeediga ja eelneva makrovaskulaarse haigusega üle 75 aastaste patsientide seas viidi läbi kardiovaskulaarne kaugtulemusi hindav pioglitasooni uuring.